These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7545721)

  • 21. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
    Ekman P
    Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments].
    Laszczyńska M; Chorzepa-Nowicka K; Wylot M; Piasecka M; Gaczarzewicz D
    Pol Merkur Lekarski; 2008 Dec; 25(150):528-30. PubMed ID: 19205388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and biological characteristics of familial benign prostatic hyperplasia.
    Sanda MG; Doehring CB; Binkowitz B; Beaty TH; Partin AW; Hale E; Stoner E; Walsh PC
    J Urol; 1997 Mar; 157(3):876-9. PubMed ID: 9072590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.
    Donohue JF; Hayne D; Karnik U; Thomas DR; Foster MC
    BJU Int; 2005 Dec; 96(9):1319-22. PubMed ID: 16287453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
    Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
    Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 30. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
    el Etreby MF; Nishino Y; Habenicht UF; Henderson D
    J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
    Wilde MI; Goa KL
    Drugs; 1999 Apr; 57(4):557-81. PubMed ID: 10235693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical results with finasteride.
    Gormley GJ; Stoner E
    Prog Clin Biol Res; 1994; 386():205-7. PubMed ID: 7528388
    [No Abstract]   [Full Text] [Related]  

  • 33. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
    Brodie AM; Son C; King DA; Meyer KM; Inkster SE
    Cancer Res; 1989 Dec; 49(23):6551-5. PubMed ID: 2479464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia.
    Vaughan D; Imperato-McGinley J; McConnell J; Matsumoto AM; Bracken B; Roy J; Sullivan M; Pappas F; Cook T; Daurio C; Meehan A; Stoner E; Waldstreicher J
    Urology; 2002 Dec; 60(6):1040-4. PubMed ID: 12475666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
    Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
    Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
    Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
    Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
    Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
    Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Benign prostatic hyperplasia--its treatment with Proscar].
    Panchev P; Neĭkov K; Simeonov P
    Khirurgiia (Sofiia); 1996; 49(1):15-8. PubMed ID: 8975081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Nacey JN; Meffan PJ; Delahunt B
    Aust N Z J Surg; 1995 Jan; 65(1):35-9. PubMed ID: 7529489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.